We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


IDT DsiRNAs Used to Map Pain Pathways in the CNS

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "IDT DsiRNAs Used to Map Pain Pathways in the CNS"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Integrated DNA Technologies (IDT) distributes the highly informative newsletter, DECODED.

In this quarter’s edition the work carried out by Dr Philippe Sarret and colleagues is discussed in detail.

Sarret’s laboratory is based at the Université de Sherbrooke (Quebec, Canada), where researchers are investigating novel ways to develop analgesics and are the first to attempt RNA interference (RNAi) via direct in vivo targeting of genes expressed in the central nervous system (CNS).

Using IDT’s Dicer-substrate RNAs (DsiRNAs), the team is specifically targeting pain-modulating pathways such as that mediated by the nueropeptide, neurotensin.

DsiRNAs have increased potency compared to traditional small interfering RNAs, achieving sustained knockdown at sub-nanomolar concentrations.

Full details of this research can be found by downloading the latest edition of IDT’s DECODED newsletter, which also provides technology overviews, interviews, and procedural recommendations relating to oligonucleotides and their applications.